Notch1调控肝脏血小板生成素的产生
该研究在小鼠中探究Notch1对肝脏血小板生成素(TPO)产生的调控作用。肝脏Notch1缺陷小鼠出现血小板减少,血浆TPO及肝脏TPO信使RNA水平显著降低,并伴有巨核细胞分化成熟受损,外源性TPO可逆转上述表现。机制上,去唾液酸血小板通过Notch1-HES5-JAK2/STAT3通路及Ashwell-Morell受体促进肝脏TPO产生。
要点
- 肝脏Notch1缺陷小鼠血浆TPO及肝脏TPO信使RNA水平显著降低,伴血小板减少和巨核细胞分化成熟受损。
- 去唾液酸血小板通过Notch1上调HES5,促进HES5与JAK2/STAT3结合并激活该通路,从而促进肝细胞TPO产生。
- 肝细胞Ashwell-Morell受体与Notch1物理结合,抑制该受体可损害Notch1信号激活和肝脏TPO产生。
核心结论
- 本研究识别出Notch1在肝脏TPO产生中的新调控作用,提示其可能成为调节TPO水平的靶点。
研究设计与样本
- 研究为小鼠实验研究,比较肝脏Notch1缺陷小鼠与对照小鼠的肝脏超微结构、肝细胞功能、血浆TPO、肝脏TPO信使RNA、血小板数量及巨核细胞分化成熟情况。
主要发现
- 对照小鼠与Notch1缺陷小鼠的肝脏超微结构和肝细胞功能相当。
- Notch1缺陷小鼠血浆TPO和肝脏TPO信使RNA水平显著降低,同时血小板数量减少、巨核细胞分化成熟受损,外源性TPO可逆转上述表现。
- Notch1缺陷肝细胞中JAK2/STAT3磷酸化显著受抑制,与RNA测序分析一致。
- 培养的Notch1缺陷肝细胞经去唾液酸血小板处理后,JAK2/STAT3磷酸化和TPO产生受损;体内实验中,肝细胞特异性Notch1缺失抑制了去唾液酸血小板给药诱导的JAK2/STAT3磷酸化和肝脏TPO产生。
- Notch1缺陷下调HES5表达而非HES1;去唾液酸血小板促进HES5与JAK2/STAT3结合,导致肝细胞JAK2/STAT3磷酸化和通路激活。
临床怎么用
- 原文结论指出Notch1可能成为调节TPO水平的靶点,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Notch signaling regulates cell-fate decisions in several developmental processes and cell functions. However, the role of Notch in hepatic thrombopoietin (TPO) production remains unclear. We noted thrombocytopenia in mice with hepatic Notch1 deficiency and so investigated TPO production and other features of platelets in these mice. We found that the liver ultrastructure and hepatocyte function were comparable between control and Notch1-deficient mice. However, the Notch1-deficient mice had significantly lower plasma TPO and hepatic TPO messenger RNA levels, concomitant with lower numbers of platelets and impaired megakaryocyte differentiation and maturation, which were rescued by addition of exogenous TPO. Additionally, JAK2/STAT3 phosphorylation was significantly inhibited in Notch1-deficient hepatocytes, consistent with the RNA-sequencing analysis. JAK2/STAT3 phosphorylation and TPO production was also impaired in cultured Notch1-deficient hepatocytes after treatment with desialylated platelets. Consistently, hepatocyte-specific Notch1 deletion inhibited JAK2/STAT3 phosphorylation and hepatic TPO production induced by administration of desialylated platelets in vivo. Interestingly, Notch1 deficiency downregulated the expression of HES5 but not HES1. Moreover, desialylated platelets promoted the binding of HES5 to JAK2/STAT3, leading to JAK2/STAT3 phosphorylation and pathway activation in hepatocytes. Hepatocyte Ashwell-Morell receptor (AMR), a heterodimer of asialoglycoprotein receptor 1 [ASGR1] and ASGR2, physically associates with Notch1, and inhibition of AMR impaired Notch1 signaling activation and hepatic TPO production. Furthermore, blockage of Delta-like 4 on desialylated platelets inhibited hepatocyte Notch1 activation and HES5 expression, JAK2/STAT3 phosphorylation, and subsequent TPO production. In conclusion, our study identifies a novel regulatory role of Notch1 in hepatic TPO production, indicating that it might be a target for modulating TPO level.
引用
- Sun Y, Tong H, Chu X, et al. Notch1 regulates hepatic thrombopoietin production. Blood. 2024. PMID: 38603632. doi:10.1182/blood.2023023559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。